Levi & Korsinsky, LLP is investigating Puma Biotechnology, Inc. (NYSE:PBYI) in connection with possible violations of federal securities laws by the Board of Directors of the Company.

To get more information, click here: http://zlk.9nl.com/puma-biotechnology. There is no cost or obligation to you.

The investigation stems from the Company’s December 2, 2014 announcement that its PB272 drug application will be delayed to the first quarter of 2016 and that the application will seek to approve the drug for the treatment of early-stage breast cancer instead of metastatic breast cancer.

If you own common stock in Puma Biotechnology and wish to obtain additional information about the investigation and our efforts to assist shareholders in recovering their losses, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/puma-biotechnology.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.